[go: up one dir, main page]

NO20033341D0 - Methods for administering epothilone analogues for the treatment of cancer - Google Patents

Methods for administering epothilone analogues for the treatment of cancer

Info

Publication number
NO20033341D0
NO20033341D0 NO20033341A NO20033341A NO20033341D0 NO 20033341 D0 NO20033341 D0 NO 20033341D0 NO 20033341 A NO20033341 A NO 20033341A NO 20033341 A NO20033341 A NO 20033341A NO 20033341 D0 NO20033341 D0 NO 20033341D0
Authority
NO
Norway
Prior art keywords
cancer
treatment
methods
epothilone analogues
administering epothilone
Prior art date
Application number
NO20033341A
Other languages
Norwegian (no)
Other versions
NO20033341L (en
NO335119B1 (en
Inventor
Rebanta Bandyopadhyay
Timothy M Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033341D0 publication Critical patent/NO20033341D0/en
Publication of NO20033341L publication Critical patent/NO20033341L/en
Publication of NO335119B1 publication Critical patent/NO335119B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033341A 2001-01-25 2003-07-24 Process for formulating an epothilone analogue for parenteral administration, pharmaceutical compositions comprising such and this compound for the treatment of cancer NO335119B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (3)

Publication Number Publication Date
NO20033341D0 true NO20033341D0 (en) 2003-07-24
NO20033341L NO20033341L (en) 2003-09-04
NO335119B1 NO335119B1 (en) 2014-09-22

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033341A NO335119B1 (en) 2001-01-25 2003-07-24 Process for formulating an epothilone analogue for parenteral administration, pharmaceutical compositions comprising such and this compound for the treatment of cancer

Country Status (10)

Country Link
JP (1) JP4633331B2 (en)
AU (1) AU2002245296B2 (en)
CA (1) CA2434526C (en)
HR (1) HRP20030677B1 (en)
IL (1) IL156578A0 (en)
MX (1) MXPA03006412A (en)
NO (1) NO335119B1 (en)
PL (1) PL207720B1 (en)
RU (1) RU2292202C2 (en)
WO (1) WO2002058700A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (en) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis of epothilone and its intermediates and analogs and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
HUE055524T2 (en) * 2007-06-01 2021-11-29 Wyeth Llc Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
JP4579351B2 (en) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis of epothilone and its intermediates and analogs and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP0995153B1 (en) * 1997-07-18 2001-11-14 Hewlett-Packard Company, A Delaware Corporation Format for passing information between devices
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
CA2320182C (en) * 1998-02-05 2008-11-25 Novartis Ag Compositions containing organic compounds
FR2775187B1 (en) * 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
HUP0105478A3 (en) * 1999-02-18 2002-08-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Also Published As

Publication number Publication date
HRP20030677A2 (en) 2004-08-31
IL156578A0 (en) 2004-01-04
PL373727A1 (en) 2005-09-05
CA2434526A1 (en) 2002-08-01
RU2003126170A (en) 2005-02-27
JP4633331B2 (en) 2011-02-16
PL207720B1 (en) 2011-01-31
MXPA03006412A (en) 2003-10-15
NO20033341L (en) 2003-09-04
CA2434526C (en) 2011-11-01
RU2292202C2 (en) 2007-01-27
HRP20030677B1 (en) 2011-10-31
WO2002058700A1 (en) 2002-08-01
AU2002245296B2 (en) 2006-12-21
NO335119B1 (en) 2014-09-22
JP2005503323A (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CY2019030I2 (en) RAPAMYCIN DERIVATIVE FOR THE THERAPEUTIC TREATMENT OF LUNG CANCER
IS6891A (en) Methods for administering epothilone analogues to treatment cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
EE200200673A (en) Quinazoline derivatives for the treatment of tumors
CY2015003I2 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CANCER
IS6917A (en) Epothilone derivatives for the treatment of difficult tumors
NO20033594L (en) Phenethanolamine derivatives for the treatment of respiratory diseases
IS7691A (en) Drug formulations for the treatment of tumors
CY2014019I1 (en) PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
NO20052894D0 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
NO20053077D0 (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
NO20040516L (en) Combination therapy for the treatment of cancer.
IS8398A (en) Drug formulations for the treatment of tumors
EE200300396A (en) Use of epothilone derivatives for the treatment of refractory tumors
IS8125A (en) Quinazoline derivatives for the treatment of cancer
NO20024775D0 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
NO20020358D0 (en) Use of etodolac for the treatment of cancer
NO20034123L (en) Procedure for the treatment of fuel
NO20033341D0 (en) Methods for administering epothilone analogues for the treatment of cancer
NO20033804D0 (en) Carbamate compounds for the treatment of pain
NO20024776D0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
NO20020784L (en) Medication for the treatment of fractures
NO20042476L (en) Use of desoxypeganine for the treatment of clinical depression
NO20012612L (en) Isonipecotamides for the treatment of integrin-mediated diseases
NO20021718L (en) Substituted pyrrols as antiproliferative agents for the treatment of cancer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: R-PHARM US OPERATING, US

MM1K Lapsed by not paying the annual fees